D. Boral Capital Reaffirms “Buy” Rating for Invivyd (NASDAQ:IVVD)

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They currently have a $9.00 price target on the stock.

Other equities research analysts also recently issued reports about the stock. EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. Morgan Stanley reduced their price objective on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a report on Wednesday, November 20th. Finally, HC Wainwright reduced their price objective on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $7.89.

Invivyd Trading Down 8.3 %

IVVD opened at $0.36 on Monday. Invivyd has a 1-year low of $0.35 and a 1-year high of $5.20. The company has a market cap of $42.79 million, a P/E ratio of -0.18 and a beta of 0.61. The company has a fifty day moving average price of $0.50 and a two-hundred day moving average price of $0.82.

Insider Buying and Selling

In related news, Director Terrance Mcguire sold 86,545 shares of the business’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $0.48, for a total transaction of $41,541.60. Following the transaction, the director now directly owns 3,170,231 shares in the company, valued at approximately $1,521,710.88. The trade was a 2.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders have sold 816,466 shares of company stock worth $423,214. 17.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Street Corp boosted its stake in Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after acquiring an additional 35,904 shares during the last quarter. Marshall Wace LLP boosted its stake in Invivyd by 4.2% in the second quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after acquiring an additional 31,992 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Invivyd in the second quarter valued at about $421,000. Cubist Systematic Strategies LLC boosted its stake in Invivyd by 66.1% in the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after acquiring an additional 53,499 shares during the last quarter. Finally, Barclays PLC boosted its stake in Invivyd by 179.6% in the third quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after acquiring an additional 75,780 shares during the last quarter. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.